GB-Liverpool: GLP Toxicology evaluation of Long-Acting Injectable (LAI) products for LTBI prevention and HCV cure

The University of Liverpool, through its LONGEVITY project funded by Unitaid, is implementing product development and commercialization of Long-Acting Injectable (LAI) formulations for malaria and tuberculosis prevention, and a hepatitis C virus cure for Low- and Middle-Income Countries (LMIC's). The University of Liverpool was awarded 32 million US dollars in early 2020 from Unitaid (https://unitaid.org/) as part of the 40 million US dollar project to fund these activities to commercialisation.https://unitaid.org/...